Aldi launches Nando's-style fakeaway range at 'peri good prices'
The Roosters range hits stores on April 3 and features a range of 'tasty' chicken and sides that were sure to 'fly off the shelves'.
Shoppers can pick up a wing roulette for £4.99, a half chicken for £3.99 or chicken breast sizzlers for £3.69.
READ MORE: Tesco shopper fumes at supermarket prank that 'could prove fatal'
Sides include 79p rainbow slaw, spicy corn on the cob and £1.49 peri-peri fries.
Extras include a £1.69 pack of spicy mixed olives and halloumi sticks with chilli jam for £2.49, The Sun reports.
Aldi also has a familiar chilli-shaped spice chart to help customers choose their preferred taste level.
Introducing the new range, Aldi said: "No need to wing it - your fakeaway feast is here!
"Snap up our tasty British chicken and sides before they fly off the shelves."
This isn't the first time shoppers have seen the range in store, it proved extremely popular last year.
Fans took to the Extreme Couponing and Bargains UK group on Facebook to share their joy.
One said: 'Don't walk, bloody run!! 'Nando's' has come to Aldi.'
Another revealed they'd bought so much of the fakeaway range she'd completely cover her kitchen counter.
Chicken lovers wanting to sample the Roosters range will need to be quick as with all Aldi Specialbuys, once it's gone it's gone.
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
2 hours ago
- Yahoo
Europe's cannabis pharmaceuticals market matures amid cautious investment
Europe's cannabis pharmaceutical market is far from a gold rush, yet it is emerging as one of the more strategic long-term plays available today. Unlike traditional drug development, which often starts with costly preclinical trials and faces high failure rates, cannabinoid medicines benefit from a rare advantage: millions of patients worldwide already use cannabinoids. This growing body of real-world evidence is helping companies to mitigate early-stage risks and design more efficient clinical trials. GW Pharmaceuticals, acquired by Jazz Pharma for $7.2 billion, is widely cited as a blueprint for end-to-end cannabinoid drug development. The British firm's success with Epidiolex, a CBD-based epilepsy treatment, demonstrated the feasibility of progressing from cultivation through to regulatory approval. In 2024, it raked in about $972.4 million in sales, and GlobalData analysis shows therapy sales may continue their upward trajectory and pull in over $1.3bn by 2030. Today, new entrants can access many of the foundational assets - active pharmaceutical ingredients, regulatory dossiers, manufacturing partnerships that GW painstakingly built, significantly lowering barriers to entry. Emerging players such as MMJ International Holdings and Zynerba Pharmaceuticals are also carving out a niche in cannabinoid-based therapies, targeting neurological disorders. Yet despite clear clinical opportunities across central nervous system (CNS) disorders, chronic pain, multiple sclerosis and cancer, capital remains a sticking point. Public markets remain cautious, and institutional investors largely absent. Instead, growth is being fuelled by family offices and strategic high-net-worth individuals drawn to de-risked licensing models, where companies out-license cannabinoid drugs to big pharma after Phase II or III trials. Some industry experts suggest the future lies in dual-track models that combine rigorous clinical research with the agility afforded by real-world data. A notable shift is underway: as US companies with consumer marketing expertise enter drug development, the blending of consumer branding with pharmaceutical discipline could create enduring competitive advantages. 'We don't have to start from scratch anymore,' said Melissa Sturgess, CEO of Ananda Pharma, during a panel discussion at Cannabis Europa 2025. 'The science is known. The data is building. Now it's about execution.' Lessons from the US: slow growth as a strategic advantage North American investors watching Europe's cannabis sector are bringing with them lessons learned through a market boom-and-bust cycle. Their cautious optimism signals that this next phase will be defined less by hype and more by discipline. 'Europe is five to six years behind the US, and that's actually a good thing,' said Anthony Coniglio, CEO and President of New Lake, a cannabis net lease real estate investment trust. 'It means there's still a chance to do things right.' The US market's rapid growth in the late 2010s, driven by celebrity-backed brands and aggressive retail expansion, also left a trail of bankruptcies and disappointed investors. Europe's more measured pace - built on pharmaceutical-grade standards, medical infrastructure and tighter regulation offers a foundation for long-term stability, though it may try the patience of entrepreneurs. Nonetheless, significant challenges remain. Experts highlighted three key reasons for investor caution: regulatory instability, with shifting rules that complicate long-term planning; ongoing uncertainty around pricing, patient access and supply-demand dynamics; and competition from more established sectors offering superior risk-adjusted returns, especially in today's high-interest rate environment. 'Cannabis doesn't operate in a vacuum,' said Tristan Gervais, managing director of investment firm T Capital. 'We're not just comparing cannabis companies to each other. We're comparing them to every other investment in the portfolio.' The tone of the discussion underscored a market correction: the era of raising capital on a pitch deck and a promise is over. Investors now demand evidence of financial discipline. 'Cash flow is everything,' stressed John Pinto, Soje Capital. 'You have to demonstrate that you can either reach profitability or survive long enough to get there.' This shift reflects a broader recalibration. Cannabis start-ups that once relied on successive funding rounds to fuel rapid growth must now show how they will operate lean, build resilient infrastructure and reduce reliance on external capital. It is no longer about brands or packaging - nor cannabis in the traditional sense. Investors are increasingly drawn to asset-light models focused on technology, logistics, and services rather than cultivation or retail, as well as non-plant-touching infrastructure such as real estate, supply chains, and pharmaceutical compliance. Experts also singled out hemp-derived, low-dose consumer products as an area of interest, particularly those that navigate restrictive THC laws while appealing to wellness-focused consumers. Crucially, companies must present themselves as well-run businesses operating in the cannabis sector, not simply 'cannabis companies.' The investor view For those seeking investment, investors offered a clear checklist: Clarity of purpose: What core problem are you solving, and why now? Operational discipline: Can you demonstrate governance, financial controls, and professional leadership? Scalable model: Is there a path to profitability without overreliance on volatile capital markets? Regulatory compliance: Are you GMP-certified, pharmaceutical-grade, and built for longevity? Capital strategy: Do you have access to future funding, or better yet, can you sustain without it? 'Without answers to these questions, you're not investable right now,' warned William Muecke, Chief Investment Officer of Artemis Growth Partners. Despite the hurdles, the consensus was clear: for those with the right approach, this remains one of the most promising moments in cannabis history. 'If you're raising money, it's tough out there,' Muecke concluded. 'But if you have money, this might be the best time to deploy it. The winners in Europe will be those who build methodically, understand regulation, and treat capital as a precious resource - not a lifeline.' "Europe's cannabis pharmaceuticals market matures amid cautious investment" was originally created and published by Pharmaceutical Technology, a GlobalData owned brand. The information on this site has been included in good faith for general informational purposes only. It is not intended to amount to advice on which you should rely, and we give no representation, warranty or guarantee, whether express or implied as to its accuracy or completeness. You must obtain professional or specialist advice before taking, or refraining from, any action on the basis of the content on our site.
Business Wire
3 hours ago
- Business Wire
UK Retailers React to Tariff Uncertainty With 76% of Exporters Diversifying Beyond the US Market, New Study Finds
LONDON--(BUSINESS WIRE)--New research from ESW and Retail Economics reveals that 76% of UK exporters are now actively diversifying beyond the US, historically the UK's largest non-EU retail market. Larger UK retailers are radically re-drawing their global growth playbooks as protectionist trade policies upend decades-old export patterns. However, 71% of small UK retailers admit they have no formal plan for sudden trade-policy shocks, a stark operational gap that could hit margins overnight. The report, ' Rethinking Reach: How UK Retailers Are Turning Trade Pressure into Global Advantage,' highlights the factors driving the urgency of this pivotal moment for British retail. The US's new baseline 10% tariff in 2025 is set to increase average duties on UK non-food exports from 2.3% to 17.2%, forcing retailers to reevaluate long-held assumptions about US viability. More than half of UK exporters would find trade to the US commercially unviable if tariffs exceed 22%. 'UK retailers are undergoing a seismic shift in their export strategies,' said Jon Sheard, VP of Northern Europe at ESW. 'Retailers can no longer be overly reliant on a single trade corridor and are pivoting to new regions, including the Middle East and Asia-Pacific, where we are seeing exponential growth.' According to the report, exports to the Middle East and North Africa surged 34% between 2021 and 2024, with the UAE now the fastest-growing UK export market outside the EU. Other growth regions include Non-EU Western Europe (+15%) and Asia-Pacific (+6%). 'Tariff volatility is reshaping the global retail landscape,' said Richard Lim, CEO of Retail Economics. 'Retailers can no longer rely solely on traditional export markets like the US. Instead, they're evaluating new trade routes and pivoting toward high-growth regions to diversify risk and capture new demand. Now is the time for exporters to plan and act. Future success will depend on the ability to adapt, localise, and seize emerging trade opportunities.' The report also finds: 77% of retailers view global brand-building as a strategic imperative. Two-thirds are willing to sacrifice profit margin for export growth. The biggest barriers to international expansion include logistics costs, operational complexity, and regulatory uncertainty. UK retailers retain a distinctive advantage, with 40% of respondents noting that the 'Made in UK' label delivers a premium perception overseas due to the country's elevated safety and regulatory standards. Many retailers are increasingly turning to strategic partners that offer fast turnkey market entry to help mitigate the challenges new market expansion presents. This can include services such as handling payments, taxes, and logistics; local cultural positioning and trust-building; targeted demand generation and localisation; and expertise in warehousing, shipping, and customs. Methodology Research was undertaken by Retail Economics in Q2 2025. This includes surveys of 200 businesses across UK non-food retail, focused on exporters, and economic modelling – drawing on annual national statistics and proprietary data to classify trade flows by retail category, region and country. Download the full report here. About ESW ESW makes worldwide ecommerce powerful and simple by partnering with the world's best-loved brands and retailers to deliver international ecommerce solutions that reduce cross-border complexity. By localising the online shopping experience, ESW creates moments that matter between brands and consumers, drives global revenue, and helps build brand loyalty. ESW addresses the complexities of international markets with tailored solutions, including frictionless checkout, fast and reliable shipping and returns, and reduced compliance and regulatory risk. ESW enables clients to navigate local markets confidently and drive long-term profitability through its unique, genuine partnership approach. With offices in New York, Dublin, Madrid, and Singapore, ESW helps the world's premier and most ambitious brands achieve growth and profitability in over 200 international markets. ESW is the only international commerce solution that is MACH certified. About Retail Economics Retail Economics is an independent economic research consultancy focused on the consumer and retail industry. We analyse the complex retail economic landscape and draw out actionable insight for our clients. Leveraging our own proprietary retail data and applying rigorous economic analysis, we transform information into points of action. Our service provides unbiased research and analysis on the key economic and social drivers behind the retail sector, helping to inform critical business decisions, giving you a competitive edge through deeper insights.
Hypebeast
6 hours ago
- Hypebeast
WASTED by Potato Head Taps Max Lamb For Its First Homeware Collection
Summary WASTED byPotato Headhas unveiled Collection 001, a new homeware line co-designed with British innovatorMax Lamb. This debut capsule transforms local waste into functional art, marrying Potato Head's 'Good Times, Do Good' ethos with Lamb's experimental, process-driven approach. Handmade in Bali by skilled local artisans, the collection embraces Indonesia's rich craft heritage while supporting the island's ambitious 99.5% landfill diversion rate. Spanning eight material families – from recycled HDPE plastics and natural dyes extracted from composted botanicals to retired hotel linens, mouth-blown glass, used cooking oils, salvaged ceramics, Styrofoam-oyster shell composites and hand-woven Balinese bamboo – the range reimagines waste as a creative resource. Employing techniques such as marigold and indigo dyeing, ceramic glazing, plastic casting, traditional weaving, and glassblowing, the collection reveals the inherent textures and colors of reclaimed materials. The result is a suite of objects, from marbled plastic chairs and refillable candles to bamboo lounge seating and hand-shaped ceramic vessels, that are both functional and poetic. Rooted in years of in-house research and the island-wide Community Waste Project, Collection 001 exemplifies a closed-loop design system that redefines material value and provenance. Each piece is one-of-a-kind, underscoring the importance of locality, process and human craftsmanship. As Max Lamb observes, 'Designers have a responsibility to justify every product we bring into the world.' Through WASTED's scalable, place-based approach, Potato Head offers a replicable blueprint for circular creativity and conscious living. Collection 001 launchesonlineon August 4 at 8 a.m. GMT/4 a.m. EST and in select stores from August 8, 2025.
